Warning: This data is provided for information purpose only. You should not start or stop any medication without consulting your care giver.
Use the Health Monitor application at http://www.healthsupportsystems.com to search for a drug by brand, generic or symptom
EPZICOM
Active Ingredients
ABACAVIR SULFATE,LAMIVUDINE
Inctive Ingredients
magnesium stearate,microcrystalline cellulose,sodium starch glycolate,FD&C Yellow No. 6,hypromellose,polyethylene glycol 400,polysorbate 80,titanium dioxide
Usage
EPZICOM Tablets, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection.
Additional important information on the use of EPZICOM for treatment of HIV-1 infection:
- EPZICOM is one of multiple products containing abacavir. Before starting EPZICOM, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir.
- In one controlled study (CNA30021), more patients taking ZIAGEN 600 mg once daily had severe hypersensitivity reactions compared to patients taking ZIAGEN 300 mg twice daily.
- As part of a triple-drug regimen, EPZICOM Tablets are recommended for use with antiretroviral agents from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.
See WARNINGS, ADVERSE REACTIONS, and Description of Clinical Studies.